Wednesday, March 29, 2017 12:05:47 AM
Just like the FDA will now take this seriously at the 4th submission in total simply because a board member switched titles and seats from board member to CEO. Perhaps they were told it won't pass due to injection into a pancreas with their previous submission level 2 and now are trying to market this as a skin cancer drug? Let's pretend like I don't already know the answer. Enlighten me
Give you a hint, they asked for clinical trials. Anyone that is willing to invest half a million would have made the trip to WA to have a face to face and ask. But you were saying?
The very same reason no outside money / real money has come in. That is a fact, no one has invested and yet not one person has actually stated why. They have had inquiries, no one has pulled the trigger.
They should stick with the dog and pony show, maybe return some money to Battelle, it will help pay for the escalating license fee, help cut down Daddy Caldwell's annual borrowing fee and allow them to perhaps, perhaps let them get permission from Battelle to re-license this to a real company that has the resources and actually execute this.
Recent RDGL News
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 09:40:48 PM
- Form QUALIF - Notice of Qualification [Regulation A] • Edgar (US Regulatory) • 12/07/2023 05:15:10 AM
- Form 1-A POS - • Edgar (US Regulatory) • 11/27/2023 10:29:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/06/2023 04:28:46 PM
- Form 1-A POS - • Edgar (US Regulatory) • 11/03/2023 09:03:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/19/2023 04:18:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 10:33:58 AM
- Form 1-A POS - • Edgar (US Regulatory) • 10/10/2023 04:05:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/04/2023 07:22:21 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM